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US28 is one of four 7 transmembrane (7TM) chemo-
kine receptors encoded by human cytomegalovirus
and has been shown to both signal and endocytose in a
ligand-independent, constitutively active manner.
Here we show that the constitutive activity and con-
stitutive endocytosis properties of US28 are separable
entities in this viral chemokine receptor. We generated
chimeric and mutant US28 proteins that were altered
in either their constitutive endocytic (US28300,
US28317, US28-NK1-ctail, and US28-ORF74-ctail) or
signaling properties (US28R129A). By using this series
of mutants, we show that the cytoplasmic tail domain
of US28 per se regulates receptor endocytosis, inde-
pendent of the signaling ability of the core domain of
US28. The constitutive endocytic property of the US28
c-tail was transposable to other 7TM receptors, the
herpes virus 8-encoded ORF74 and the tachykinin NK1
receptor (ORF74-US28-ctail and NK1-US28-ctail). Dele-
tion of the US28 C terminus resulted in reduced con-
stitutive endocytosis and consequently enhanced sig-
naling capacity of all receptors tested as assessed by
inositol phosphate turnover, NF-B, and cAMP-
responsive element-binding protein transcription as-
says. We further show that the constitutive endocytic
property of US28 affects the action of its chemokine
ligand fractalkine/CX3CL1 and show that in the ab-
sence of the US28 C terminus, fractalkine/CX3CL1 acts
as an agonist on US28. This demonstrates for the first
time that the endocytic properties of a 7TM receptor
can camouflage the agonist properties of a ligand.
Endocytosis of 7 transmembrane (7TM)1 G protein-coupled
receptors is a mechanism that allows control of an appropriate
cell surface receptor density in a given physiological setting.
Typically, a receptor is activated by an agonist and initiates a
signaling cascade before it undergoes endocytosis. However,
there are receptors that can signal in a ligand-independent
manner, the so-called constitutively active receptors. For some
of these, constitutive internalization is an accompanying effect,
e.g. for mutant parathyroid hormone receptors (PTH1Rc) (1),
the constitutively active mutants of the angiotensin II (1A)
receptor (2), or the human complement factor C5a receptor (3).
Two examples of constitutively endocytosing 7TM receptors
have been described in the chemokine system, one of which is
the CXCR4 receptor. However, its constitutive internalization
rate with 2.5% of total surface receptor/min in the absence of
ligand is rather slow (4). The other receptor is US28, a 7TM
receptor encoded by human cytomegalovirus (HCMV) that has
been shown to both signal (5, 6) and endocytose in a ligand-
independent manner at the rate of 7% of the cell surface
pool/min (7).
Of the four chemokine receptors encoded by this large DNA
virus, UL33, UL78, US27, and US28 (8), US28 is so far the
most extensively characterized receptor. It binds several CC-
chemokines such as MIP-1/CCL3, MCP-1/CCL2, MIP-1/
CCL4, and RANTES/CCL5 (9) as well as the CX3C-chemokine
fractalkine/CX3CL1 with high affinity (10). However, despite
its rather broad-spectrum ligand repertoire, US28 signals in-
dependently of any ligand in a highly constitutive manner.
US28 stimulates the G protein Gq/phospholipase C pathway
and up-regulates cellular transcription factors including the
nuclear factor–B (NF-B) and the cAMP-responsive element-
binding protein (CREB) (5, 6) in the absence of any ligand.
US28 has been implicated to be important for the viral life cycle
of HCMV; for example, it has been suggested to enhance cell-
cell fusion, demonstrating its potential importance in the cell-
to-cell spread of HCMV in vivo (10, 11). In addition, US28 has
been linked to pathogenic diseases like atherosclerosis and
restenosis, following observations that HCMV-infected smooth
muscle cells are able to migrate toward a CC-chemokine gra-
dient consisting of the US28-ligands RANTES/CCL5 and MCP-
1/CCL2 (12).
In contrast to endogenous chemokine receptors, which are
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predominantly located on the cell surface, only a fraction of
US28 (at most 20%) is expressed on the cell surface. The
majority of the receptor is found in the membranes of intracel-
lular organelles that include components of the endocytotic
pathway, in particular multivesicular late endosomes or mul-
tivesicular bodies (7). In fact, US28 has been shown to undergo
rapid and constitutive agonist-independent endocytosis, simi-
lar to that of activated endogenous chemokine receptors. More
specifically, the tonic internalization rate of US28 receptors is
comparable with that of activated chemokine receptors (i.e.
SDF-1 induced internalization in CXCR4 (4)). Interestingly,
this seems to be a -arrestin-independent mechanism, because
the trafficking patterns of US28 are unaltered in mouse em-
bryonic fibroblasts devoid of both -arrestin 1 and -arrestin 2
proteins (13).
We have used truncated and chimeric US28 receptors to
begin to elucidate the domain(s) of US28 necessary for consti-
tutive signaling and endocytosis and have used these mutants
to assess the functional consequences of altering receptor sig-
naling and trafficking.
EXPERIMENTAL PROCEDURES
Materials—Substance P was purchased from Peninsula (St. Helens,
Merseyside, UK); CX3CL1 (i.e. the chemokine domain corresponding to
amino acids 1–69 of fractalkine) was from R & D Systems; and GCP-
2/CXCL6 and IL-8/CXCL8 were purchased from PeproTech (London,
UK). The radioligands 125I-GCP-2/CXCL6, 125I-CX3CL1, and
125I-sub-
stance P were obtained from Amersham Biosciences. IL-8/CXCL8 was
labeled with 125I using the IODO-GEN method (Pierce) according to the
manufacturer’s protocol. 125I-Labeled IL-8/CXCL8 was separated from
free iodine (99%) using a 25-cm, 10-ml Sephadex G-25 gel filtration
column (ICN Pharmaceuticals Inc., Costa Mesa, CA). Iodine incorpora-
tion and specific activity were determined via precipitation of the pro-
tein by the trichloroacetic acid method (14). The H4A3 LAMP1 antibody
developed by J. T. August and J. E. K. Hildreth was obtained from the
Developmental Studies Hybridoma Bank developed under the auspices
of the NICHD, National Institutes of Health, and maintained by the
University of Iowa, Dept. of Biological Sciences, Iowa City.
cDNA Constructs—The DNA coding the US28 chemokine receptor
(AD169 strain of HCMV) was kindly provided by Timothy N. C. Wells
(Serono Pharmacological Research Institute, Geneva, Switzerland).
The R129A mutant of US28 was constructed by site-directed mutagen-
esis, and the receptor was re-introduced into the multiple cloning site of
the expression vector. The truncated versions of the US28 receptor,
US28300 and US28317, were constructed by inserting a STOP codon
following residues Gln-300 or Val-317 of the wild type US28 receptor,
respectively (see Fig. 2A), and thereafter introducing an EcoRI site for
fusion into the multiple cloning site of the expression vector. The
receptor chimeras ORF74-US28-ctail and NK1-US28-ctail were created
as follows. The ORF74 receptor carrying the US28-ctail (Table I, D) was
constructed by oligonucleotide-directed mutagenesis, with oligonucleo-
tides consisting of a 10–15-bp overlap from both the C-terminal trun-
cated part of the ORF74 receptor (truncation at residue Arg-335) and
the C terminus (residues Gln-300 to Pro-354) of the US28 receptor.
Likewise, the NK1 receptor bearing the C-terminal domains of US28
(Table I, E) was constructed by fusing the C terminus of the wild type
US28 receptor (residues Gln-300 to Pro-354) to the NK1 receptor trun-
cated at residue Arg-313. The receptor chimeras US28-NK1-ctail (Table
I, F) and US28-ORF74-ctail (Table I, G) were created by fusing the
C-terminal truncated part of the wild type US28 receptor (truncation at
residue Arg-299) to either the C terminus of the human NK1 receptor
(residues Leu-314 to Ser-407) or the C terminus of the ORF74 receptor
(residues Gln-336 to Thr-355). All constructs were tagged by inserting
the 9-amino acid sequence (YPYDVPDYA) recognized by the anti-HA 11
mouse monoclonal antibody immediately after the N-terminal initiate
methionine of the respective receptor DNAs. Addition of the N-terminal
HA tag did not impair binding of the respective ligands to any of the
TABLE I
C-terminal tails of the US28, NK1, and ORF74 receptor chimeras beginning with the conserved NPXXY motif
Receptor chimeras were generated by exchanging the cytoplasmic tails 8 residues proximal to the NPXXY motif at the end of TM7. The dotted
line indicates the position of the C-terminal “swap”; A, C termini of the wild type US28 receptor; B, ORF74 receptor; C, the tachykinin
NK1-receptor. D, the C termini of the ORF74-US28 chimera; E, the NK1-US28 chimera; F, the US28-NK1 chimera; and G, US28-ORF74 chimera.
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tested receptors. All constructs were cloned into the eukaryotic expres-
sion vector pTEJ8 (15) and verified by DNA sequencing.
Transfections and Cells—COS-7 cells were grown at 10% CO2 and
37 °C in Dulbecco’s modified Eagle’s medium 1885 supplemented with
10% fetal calf serum, 2 mM glutamine, and 100 units/ml penicillin
G/streptomycin. HEK293 cells were grown at 5% CO2 and 37 °C in
Dulbecco’s Ham’s F-12 medium supplemented with 10% fetal calf se-
rum, 2 mM glutamine, and 100 units/ml penicillin G/streptomycin. Cells
were transiently transfected with the respective amounts of cDNA
using the calcium phosphate precipitation method (16) or with Lipo-
fectAMINE 2000 (Invitrogen) in the luciferase-reporter assay.
Phosphatidylinositol Assay—Inositol phosphate turnover in COS-7
cells was performed as described previously (6). In brief, COS-7 cells
(2.5  105 cells/well) were incubated in 12-well plates (Biotechline,
Denmark) for 24 h with 5 Ci of myo-[3H]inositol, followed by a washing
step in 20 mM HEPES buffer, pH 7.4, supplemented with 140 mM NaCl,
5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10 mM glucose, and 0.05% (w/v)
bovine serum albumin. Subsequently, cells were incubated in 0.5 ml of
buffer supplemented with 10 mM LiCl at 37 °C for 60 min in the
presence of various concentrations of chemokines. The incubation was
stopped by aspiration of the binding buffer and addition of 1 ml of
ice-cold 10 mM formic acid. After incubation on ice for 60 min, the
generated [3H]inositol phosphates were purified using Dowex AG 1X8
anion-exchange columns (Bio-Rad) and counted by liquid scintillation.
Reporter Gene Assays—COS-7 and HEK293 cells were transfected
with reporter plasmids as described (6). In short, cells (35,000 cells/
well) were seeded out in 96-well plates and transiently transfected with
either a “reporter/cDNA mixture” consisting of pFA2-CREB and pFR-
Luc reporter plasmids (PathDetect CREB Trans-Reporting System,
Stratagene) or pNF-B-Luc (PathDetect Cis-Reporting System, Strat-
agene) and the indicated amounts of receptor DNA. Following transfec-
tion, cells were treated with the respective compounds in an assay
volume of 100 l for 24 h. When treated with chemokines, cells were
maintained in low serum (2.5%) throughout the experiments. The assay
was terminated with the addition of luciferase assay reagent (LucLite,
Packard Instrument Co.), and luminescence was measured in a Top-
Counter (Top Count NXTTM, Packard Instrument Co.) for 1 s. Lumi-
nescence values are given as relative light units (RLU). All reporter-
gene experiments were conducted in parallel in HEK293 and COS-7
cells and showed comparable results; however, the chemokine stimula-
tion assays in HEK293 cells yielded a better signal-to-noise ratio.
Radioligand Binding Experiments—Whole cell radioligand binding
assays were performed on transiently transfected COS-7 cells. 24 h
post-transfection, cells were transferred to 24-well culture plates, and
the number of cells seeded per well was such as to obtain 5–10% specific
binding of the added radioactive ligand. Homologous competition bind-
ing was performed for 3 h at 4 °C in 0.5 ml of binding buffer containing
12 pM of the respective radioligands 125I-GCP-2/CXCL6 or 125I-CX3CL1
plus unlabeled ligand in the concentrations indicated. The binding
buffer consisted of 50 mM HEPES buffer, pH 7.4, supplemented with 1
mM CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin. Following
incubation cells were washed quickly four times in 4 °C binding buffer
supplemented with 0.5 M NaCl to reduce unspecific binding. Nonspecific
binding was determined in the presence of 0.1 M of the corresponding
unlabeled ligand. 125I-Substance P binding was conducted in 50 mM
Tris-HCl buffer, pH 7.4, supplemented with 150 mM NaCl, 5 mM MnCl2,
0.1% (w/v) bovine serum albumin, and 40 g/ml bacitracin. Following
binding, cells were washed twice in ice-cold buffer. Nonspecific binding
was determined in the presence of 0.1 mM of unlabeled ligand. IC50
values were determined by nonlinear regression using GraphPad Prism
2.1 (GraphPad Software, San Diego), and Bmax values were calculated
from the homologous competition binding curves using the equation
Bmax  B0  (IC50/[L]), where B0 indicates the specific bound radioli-
gand, and [L] indicates the concentration of free radioligand. Saturation
assays were performed for 3 h at 4 °C in 0.25 ml of binding buffer
containing increasing amounts of 125I-CX3CL1 radioligand, and nonspe-
cific binding was determined in the presence of 0.1 M of the unlabeled
ligand.
Radioligand Endocytosis Assays—Transiently transfected COS-7
cells were plated in 24-well culture plates and allowed to grow for 2
days. Cells were washed once with ice-cold phosphate-buffered saline
and incubated with 125I-CX3CL1 (0.3 nM) or
125I-IL-8/CXCL8 (1.5 nM)
for 3 h at 4 °C in 50 mM HEPES buffer, pH 7.4, supplemented with 1 mM
CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin. Subsequently,
cells were washed twice with cold binding buffer supplemented with 0.5
M NaCl, followed by one wash with prewarmed DMEM at 37 °C to
remove free ligand. Cells were then incubated in DMEM at 37 °C to
allow receptor internalization. Internalization was stopped by aspirat-
ing the medium and returning the samples on ice. For each time point,
one set of cells was immediately lysed in 0.2 M NaOH, whereas a second
set of cells was subjected to an acidic wash to remove surface-bound
chemokine. Briefly, cells were rinsed once in ice-cold DMEM (pH 2.0),
followed by two 3-min washes in the same medium, and finally lysed in
0.2 M NaOH. Samples were counted in a gamma-counter. Control bind-
ing experiments were conducted and showed that the acidic wash fully
removed surface-bound chemokine while leaving the receptor surface
intact.
Immunofluorescence—Cells expressing the receptor constructs 2
days after transfection were used for immunofluorescence. 24 h post-
transfection, cells were plated to coverslips and allowed to grow for 24 h.
Living cells were fed monoclonal anti-HA 11 antibody (Covance, Berke-
ley, CA) for 30 min to label receptors. For co-localization studies with
transferrin, cells were starved in serum-free medium for 60 min and fed
Texas Red-conjugated transferrin (Molecular Probes) for 30 min. Sub-
sequently, cells were fixed with 3% paraformaldehyde in phosphate-
buffered saline for 20 min at room temperature and permeabilized with
0.1% Triton X, essentially as described (17). For co-localization studies
with LAMP1, receptors were labeled with affinity-purified rabbit anti-
mouse antibody to convert the HA-11 IgG1-labeled receptors into rab-
bit-IgGs and subsequently visualized with a secondary goat anti-rabbit
FITC (Jackson ImmunoResearch) antibody. In parallel, cells were
stained with the LAMP1 H4A3 IgG1 antibody from Developmental
Studies Hybridoma Bank and visualized with a CY5-conjugated sec-
ondary donkey anti-mouse antibody (Molecular Probes). Controls (omis-
sion and cross-staining with either first or secondary antibodies) were
made in order to verify that the staining was specific to both receptor
and LAMP1, respectively. Following staining, cells were mounted in
Vectashield Mounting Medium (Vector Laboratories) and analyzed us-
ing a Zeiss fluorescence microscope equipped with a Coolsnap CCD
camera and a Zeiss LSM510 META Axioplan 2 confocal microscope. We
emphasize that all the antibody feeding experiments were conducted in
parallel in both HEK293 and COS-7 cells, but we could not detect any
substantial differences between these two cell lines.
RESULTS
An Inactive Signaling Mutant of US28 Is Constitutively En-
docytosed—We first asked whether the constitutive endocytosis
of US28 was a consequence of its high constitutive signaling
activity (5, 6). To examine this, we generated a US28 mutant
that was no longer constitutively active. The conserved DRY
motif located at the boundary of transmembrane helix 3 and
the second intracellular loop of most 7TM receptors plays a
pivotal role in G protein activation (18, 19). We created a
mutant US28 receptor where the arginine in this DRY motif
was substituted with an alanine (US28 R129A). As expected,
US28 R129A no longer showed constitutive signaling proper-
ties when tested in inositol phosphate turnover assays (Fig. 1O,
black bar). To directly examine constitutive endocytosis, we
conducted antibody feeding experiments, because this experi-
mental setup allows us to assess distributions of receptors that
were accessible to the HA antibody during a 30-min incubation
period (for details see “Experimental Procedures”). Further-
more, this approach guarantees that the labeled receptors were
in fact intact and reached the cell surface and were not merely
stuck intracellularly or retained in the endoplasmatic reticu-
lum due to improper protein folding. The cellular distribution
of US28 R129A (Fig. 1, A–G) was indistinguishable from that of
the wild type US28 receptor (H–N). Both US28 wild type and
US28 R129A receptors were localized in early endosomes and
lysosomes (G and N, respectively) as assessed by co-localization
studies with the early endosomal marker transferrin (A–C and
H–J, red) and the lysosomal marker lysosomal-associated
membrane protein 1 (LAMP1) (D–F and K–M, blue). In addi-
tion, US28-containing vesicles that lacked these markers were
also observed (green). These data are in excellent agreement
with the elaborate study of Fraile-Ramos et al. (7), where
localization of US28 was assessed in HeLa cells. The same
co-localization profiles were found in COS-7 cells (data not
shown). We further verified that both US28wt and USR129A
receptors were expressed on the cell surface in comparable
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amounts by conducting whole cell 125I-CX3CL1 radioligand
binding experiments. Because these experiments are per-
formed at 4 °C, no endocytosis of receptors occurs, and there-
fore this assay represents a “snapshot” of the steady state level
of receptors on the cell surface. Fig. 1P shows a homologous
displacement curve for both US28wt (‚) and US28 R129A (),
and Table II shows that the Bmax levels of US28R129A-express-
ing cells were comparable with those of US28wt receptor-ex-
pressing cells. In addition, we tested the constitutive endocy-
tosis rate of US28wt and US28 R129A by radioligand
internalization assays with the chemokine ligand 125I-CX3CL1.
When compared with the wild type receptor US28 (Fig. 1Q, ‚),
US28 R129A (Fig. 1Q, ) was constitutively internalized at
37 °C at a slightly higher rate than the wild type US28 recep-
tor. Summarized, these data show that constitutive activity of
US28 is not necessary for its constitutive endocytosis.
Effect of Full or Partial Truncation of the C Terminus on the
Trafficking and Signaling, Properties of US28—We next de-
signed a set of experiments to determine what domain(s) in
US28 were mediating its constitutive endocytosis. A very re-
cent study (20) showed that the C terminus of US28 is consti-
tutively phosphorylated and that the deletion of all phospho-
rylation sites resulted in increased surface expression of US28.
Moreover, palmitoylation of the C terminus of various 7TM
receptors (for review see Ref. 21) and for one chemokine recep-
TABLE II
Steady state surface expression of US28 constructs
The table shows KD  S.E. for the indicated number of experiments
(n), followed by Bmax  S.E.
Receptor KD Bmax
nM fmol/105 cells
US28wt 0.23  0.06 (3) 13.2  1.6
US28R129A 1.5  0.3 (2) 21.6  4.2
US28300 0.79  0.01 (3) 128.4  4.1
US28317 0.79  0.15 (2) 67.9  4.3
US28-NK1-ctail 0.83  0.12 (2) 86.1  1.1
US28-ORF74-ctail 0.66  0.07 (2) 66.1  5.6
FIG. 1. Internalization and signaling properties of the US28 mutant R129A. A–N, HEK293 cells were transiently transfected with wild
type US28 (A–G) or US28 R129A (H–N) cDNAs, and an antibody feeding experiment was conducted as described under “Experimental Procedures.”
US28wt (A) and US28 R129A (H) co-localize with the early recycling endosomal marker transferrin (B and I), as shown in the overlays (C and J),
respectively. Receptor, green; transferrin, red; and overlay, yellow. US28wt (D) and US28 R129A (K) co-localize with the lysosomal marker LAMP1
(E and L), as shown in the overlays F and M, respectively. Receptor, green; LAMP1, blue; overlay, light blue. G and N, triple overlay of US28wt
(G, green) or US28 R129A (N, green) with transferrin (red) and LAMP1 (blue). Scale bars, 10 m. O, constitutive inositol phosphate turnover was
measured in COS-7 cells transiently transfected with 40 g of US28 wt (white bar) or US28R129A (black bar) DNAs. 40 g of vector DNA (gray
bar) served as a control. Shown are means S.E. of 3 independent experiments carried out in triplicate. P, surface expression of the wild type US28
and the US28 R129A receptor determined by whole cell binding of the chemokine ligand 125I-CX3CL1/fractalkine. Whole cell homologous
competition binding was performed on COS-7 cells transiently transfected with 40 g of either US28 wild type (‚) or US28 R129A () receptor
DNAs. One day post-transfection, cells were labeled with 125I- CX3CL1/fractalkine and incubated with increasing amounts of cold chemokine ligand
as indicated. Data are mean  S.E. from 2 experiments performed in duplicate. Q, COS-7 cells were transiently transfected with either US28 wild
type (‚) or US28 R129A () receptor cDNAs, and receptor internalization was measured with 125I-CX3CL1 for 60 min at 37 °C. Data are means 
S.E. from 3 experiments performed in triplicate.
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tor, the CCR5 receptor, has been reported to be essential for (i)
the expression of a functional receptor on the cell surface and
for (ii) the endocytic properties of these receptors (22–24). How-
ever, to date no study has been reported that palmitoylation of
the C terminus plays a role in the function of US28 or any other
viral chemokine receptor. We first tested whether truncation of
the last 36 residues of the US28 C terminus (US28317),
thereby leaving its putative palmitoylation site intact, would
alter the endocytic properties of US28. US28317 protein was
expressed predominantly on the surface of HEK293 cells (Fig.
2B, middle panel) as opposed to US28 wild type receptor, which
was predominantly located intracellularly (Fig. 2B, left panel).
Full truncation of the last 54 residues of the US28 C terminus
(US28300) resulted in the same phenotype as US28317,
with the majority of US28300 protein expressed on the cell
surface (Fig. 2C, right panel).
Next we examined whether the US28300 and US28317
receptor proteins were still functionally coupled to G proteins.
As we have demonstrated previously, US28 is a constitutively
active receptor that signals via a Gq/phospholipase C-coupled
pathway and up-regulates transcription factors such as NF-B
and cAMP-responsive element-binding protein (CREB) (5, 6).
Fig. 2C shows that the partial or full deletion of the C terminus
of US28, US28317 (gray bar), or US28300 (hatched bar),
respectively, did not impair constitutively induced inositol
phosphate turnover in COS-7 cells when compared with wild
type US28 (black bar). In fact, the fully truncated US28300
(hatched bar) protein showed a slightly enhanced signaling
profile compared with the other receptors. When tested for
their ability to up-regulate reporter genes like NF-B or CREB,
both US28317 (f) and US28300 () were able to constitu-
tively induce NF-B-luciferase (Fig. 2D) and CREB-luciferase
(Fig. 2E) activity above control levels (Fig. 2, D and E, E) in a
gene dose-dependent manner.
These findings show that the C terminus of US28 is involved
in the endocytotic trafficking of the receptor, but it is not
necessary for the constitutive activity of this viral protein.
Together with the data from Fig. 1, these results suggest that
the constitutive activity and endocytosis of US28 are separable
entities.
US28 C Terminus Conveys Constitutive Endocytosis Proper-
ties to Other 7TM Receptors—Although the signaling properties
of US28 were not impaired by deletion of its C terminus, the
endocytic properties of US28 were significantly altered, i.e. the
truncated receptors were predominantly expressed on the cell
surface. To assess whether the US28 C terminus contains
signals for constitutive endocytosis of 7TM receptors in gen-
eral, we exchanged the C termini of both a virally encoded,
constitutively active receptor, the herpes virus 8-encoded 7TM
receptor ORF74 (25), and a nonvirally encoded nonconstitu-
tively active 7TM receptor (the human tachykinin NK1 recep-
tor) with the last 55 C-terminal amino acids of US28 (see Table
I, D and E, respectively). Like US28, ORF74 constitutively
signals via the Gq/phospholipase C pathway and induces
NF-B transcription (26, 27). In terms of cellular localization,
however, ORF74 differs from US28 in that it is predominantly
expressed on the cell surface of transfected cells (26) (Fig. 3A,
green panel). When expressed in HEK293 cells, a significant
portion of the receptor chimera ORF74-US28-ctail (Table I, D)
was now found intracellularly (Fig. 3B) as assessed by antibody
FIG. 2. Localization and signaling of wild type and C-terminally truncated versions of US28. A, amino acid sequences for C termini of
US28wt and truncated sites for US28300 and US28317. B, HEK293 cells were transiently transfected with either wild type US28 receptor (left
panel), US28317 (middle panel), or US28300 (right panel). 48 h post-transfection, cells were incubated with antibodies directed against the
N-terminal HA tags of the respective receptors, fixed, and permeabilized, and receptors were visualized with fluorescent antibodies (see
“Experimental Procedures”). Scale bars, 10 m. C, constitutive inositol phosphate turnover was measured in COS-7 cells transiently transfected
with 40 g of US28wt (black bar), US28317 (gray bar), or US28300 (hatched bar) DNAs. 40 g of vector DNA (white bar) served as a control.
Shown are means S.E. of 3 independent experiments carried out in triplicate. D, induction of NF-B-driven luciferase expression was determined
in transiently transfected COS-7 cells (35,000 cells/well). Cells were co-transfected with 50 ng of NF-B-luciferase vector and increasing amounts
of either pTEJ8 vector DNA (E) as a control, US28wt (‚), US28300 (), or US28317 (f) DNAs. E, activation of CREB-luciferase was determined
in COS-7 cells (35,000 cells/well) co-transfected with a CREB/luciferase/vector mixture (for details see “Experimental Procedures”) and with
increasing amounts of either vector DNA (E) as a control or US28wt (‚), US28300 (), or US28317 (f) DNAs. For both reporter assays,
representative experiments out of at least four independent experiments performed in quadruplicate are shown. RLU was as measured in a
Packard TopCounter (1 s/well).
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feeding experiments and co-localization studies with the early
recycling endosomal marker transferrin (Fig. 3B, red panel)
and the lysosomal marker LAMP1 (Fig. 3B, blue panel).
Hence, we propose that the C terminus of US28 can serve as
a transposable constitutive endocytic module. Furthermore,
the ability of the US28 c-tail to stimulate endocytosis of ORF74
did not appear to depend on its constitutive signaling activity.
Truncation of the C terminus of ORF74 has been shown to
abolish its constitutive and ligand-induced signaling activity
(26). In fact, when we substituted the ORF74 c-tail with that of
US28 and tested this chimera in inositol phosphate turnover
(Fig. 3C), NF-B (Fig. 3D), or CREB-luciferase (Fig. 3E) acti-
vation assays, the ORF74-US28-ctail receptor () was inactive
as opposed to the wild type ORF74 receptor (‚), which showed
gene dose-dependent activation in all three signaling assays.
Although the ORF74 wild type receptor activity could be fur-
ther stimulated by the addition of the chemokine agonist GRO-
/CXCL1 (28), treatment of cells expressing the ORF74-US28-
ctail receptor with agonist concentrations up to 1 M did not
elicit a response above base line in any of the assays employed
(data not shown). We verified that this was not due to a lack of
binding capacity of the ORF74-US28-ctail chimera to chemo-
kines and/or profound differences in steady state receptor sur-
face expression. The chemokine GCP-2/CXCL6 (Fig. 3F) bound
ORF74-US28-ctail () with affinities comparable with those of
wild type ORF74 receptor (‚). The Bmax values (see inset in Fig.
FIG. 3. ORF74 wild type receptor and ORF74-US28-ctail chimeric receptor signaling and sorting properties. HEK293 cells were
transiently transfected with either ORF74 wild type receptor (A) or ORF74-US28-ctail (B) receptor DNA. Cells were incubated with an HA antibody
for 30 min, and co-localization (right lower panel in A and B) with the early endosomal markers transferrin (red) and the lysosomal marker LAMP1
(blue) was assessed as described under “Experimental Procedures.” Scale bars, 10 m. C, gene dose-dependent inositol phosphate turnover
measured in COS-7 cells transiently transfected with increasing concentrations of ORF74 wild type receptor (‚) or ORF74-US28-ctail receptor ()
DNAs. 40 g of vector DNA (E) served as a control. Shown are means  S.E. of 3 independent experiments carried out in triplicate. D, induction
of NF-B-driven luciferase expression in transiently transfected COS-7 cells. Cells were co-transfected with NF-B-luciferase vector and increasing
amounts of either pTEJ8 vector DNA (E), ORF74 wild type receptor (‚), or the ORF74-US28ctail receptor () DNAs. E, activation of CREB-
luciferase in COS-7 cells. Cells were co-transfected with a CREB/luciferase/vector mixture and with increasing amounts of either vector DNA (E)
as a control or ORF74 wild type receptor (‚) or the ORF74-US28ctail receptor () DNAs. For both reporter assays, representative experiments
out of at least four independent experiments performed in quadruplicate are shown. F, surface expression of the wild type ORF74 and the
ORF74-US28-ctail receptor determined by whole cell binding of the CXC-chemokine ligand 125I-GCP-2/CXCL6. Whole cell homologous competition
binding was performed on COS-7 cells transiently transfected with 40 g of either ORF74 wild type (‚) or ORF74-US28-ctail () receptor DNAs.
One day post-transfection, cells were labeled with 125I-GCP-2/CXCL6 and incubated with increasing amounts of cold chemokine ligand as
indicated. Inset, Bmax values for
125I-GCP-2/CXCL6 binding on ORF74 wild type (open bar) and ORF74-US28-ctail (black bar) are given in fmol/105
cells. Data are means  S.E. from 3 experiments performed in duplicate. G, endocytosis of ORF74wt and ORF74-US28-ctail proteins with the
neutral chemokine ligand 125I-IL-8/CXCL8. COS-7 cells were transiently transfected with either US28 wild type (‚) or US28-ORF74-ctail ()
constructs, and receptor internalization was measured with 1.5 nM 125I-IL-8/CXCL8 for 60 min at 37 °C. Data are mean  S.E. from 2 experiments
performed in triplicate.
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3F) and IC50 values of GCP-2/CXCL6 were 16.5 1.95 fmol/10
5
cells and 0.50  0.08 nM for the wild type and 11.0  1.74
fmol/105 cells and 0.45  0.08 nM for the ORF74-US28-ctail
receptor. Hence, the steady state surface receptor levels of
these two receptors differed by less than 50%, a difference that
we do not believe can account for the signaling mute phenotype
of the ORF74-US28-ctail chimera. To assess more quantita-
tively the endocytosis rates of the wild type ORF74 receptor
and the ORF74-US28-ctail chimera, we conducted radioligand
internalization assays with the neutral chemokine ligand 125I-
IL-8/CXCL8 (Fig. 3G). When compared with the wild type
ORF74 (Fig. 3G, ‚) receptor, the ORF74-US28-ctail (Fig. 3G,
) chimera was internalized at 37 °C at a significantly higher
rate than the wild type ORF74 receptor. These data show that
the US28 C terminus is able to transfer its constitutive inter-
nalization properties to another viral chemokine receptor.
We further validated the ability of the US28-ctail to promote
constitutive endocytosis using a nonviral and nonconstitutively
active 7TM receptor. We chose the tachykinin NK1 receptor,
because it is known to utilize similar signaling pathways, i.e.
the Gq/phospholipase C pathway and NF-B transcription in a
nonconstitutive, ligand-dependent manner. In addition, the
trafficking properties of the NK1 receptor have been exten-
sively studied, and the involvement of its C terminus in inter-
acting with proteins from the endocytotic machinery is well
documented (29–31). The wild type NK1 receptor is typically
found on the surface of transfected cells (Fig. 4A), whereas
upon stimulation with the agonist substance P, receptors rap-
idly internalize (Fig. 4B) (30). The replacement of the NK1-ctail
with the last 55 residues of the US28 receptor (NK1-US28-ctail,
see also Table I, E) generated a receptor that was found intra-
cellularly both in the absence (Fig. 4C) or presence (Fig. 4D) of
substance P. Fig. 4E shows that both the wild type NK1 (E) and
the NK1-US28-ctail chimera () bind the radioligand 125I-
substance P with comparable affinities, with an IC50 of 0.33 
0.07 nM (n 5) for the NK1-wild type receptor and 0.23 0.10 nM
(n  10) for the NK1-US28-ctail receptors. Steady state surface
receptor levels were 37.12 6.4 nM (n 5) for the NK1 wild type
receptor (inset in Fig. 4E, white bar) and 22.95  4.9 nM (n  10)
for the NK1-US28-ctail chimera (inset in Fig. 4E, black bar).
However, the swap of the US28 C terminus onto the NK1
receptor did not confer constitutive signaling to this receptor,
FIG. 5. Sorting and signaling of the US28-ORF74-ctail and
US28-NK1-ctail receptor chimeras. HEK293 cells were tran-
siently transfected with either US28-ORF74-ctail receptor (A) or
US28-NK1-ctail (B) receptor DNAs. An antibody feeding experiment
was performed with HA antibody for 30 min, and cells were fixed,
permeabilized, and stained with a FITC-conjugated secondary anti-
body and imaged by fluorescence microscopy. Scale bars, 10 m. C,
constitutive inositol phosphate turnover in COS-7 cells transiently
transfected with increasing concentrations of wild type US28 receptor
(‚), US28-ORF74-ctail receptor (), or US28-NK1-ctail receptor (f)
DNAs. Cells transfected with vector pTEJ8 DNA (E) served as a
control. D, CREB-luciferase activity measured in COS-7 cells co-
transfected with a CREB/luciferase/vector mixture (for details see
“Experimental Procedures”) and the indicated amounts of US28 wild
type (‚), US28-ORF74-ctail (), or US28-NK1-ctail (f) receptor
DNAs. Cells co-transfected with the respective reporter DNAs and
increasing amounts of pTEJ8 vector DNA (E) served as a control. E,
induction of NF-B-driven luciferase expression in COS-7 cells co-
transfected with 50 ng of NF-B-luciferase DNA and increasing con-
centrations of US28 wild type receptor (‚), US28-ORF74-ctail recep-
tor (), or US28-NK1-ctail receptor (f) DNAs. US28. For all reporter
assays, representative experiments out of at least four independent
experiments performed in quadruplicate are shown.
FIG. 4. The cellular distribution and signaling activity of the tachykinin NK1 wild type and NK1-US28-ctail receptors. HEK293 cells
were transiently transfected with wild type NK1 receptor (A and B) or NK1-US28ctail receptor DNAs (C and D). 2 days following transfection, cells
were incubated with an HA antibody for 30 min and either fixed (A and C) or treated with 1 M substance P for 10 min (B and D) and fixed,
permeabilized, and stained with a FITC-conjugated secondary antibody. Scale bars, 10 m. E, surface expression of the wild type NK1 and the
NK1-US28 receptor determined by whole cell binding of
125I-substance P (SP). Whole cell homologous competition binding was performed on COS-7
cells transiently transfected with 40 g of either NK1 wild type (E) or NK1-US28 () receptor DNAs. One day post-transfection, cells were labeled
with 125I-substance P and incubated with increasing amounts of cold ligand as indicated. Inset, Bmax values for
125I-substance P binding on NK1
wild type (open bar) and NK1-US28 (black bar) are given in fmol/10
5 cells. Shown is a representative experiment performed in duplicate. F, inositol
phosphate turnover in response to increasing concentrations of substance P in COS-7 cells transiently transfected with 40 g of NK1wt (E) or
NK1-US28-ctail () receptors. 100% corresponds to the maximally obtained activity in the wild type receptor. Data are mean  S.E. from 3
experiments performed in triplicate.
Cellular Trafficking of US28 19479
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
because both the wild type NK1 receptor (E) and the NK1-
US28-ctail receptor () required stimulation with substance P
to induce inositol phosphate accumulation (Fig. 4F) or NF-B-
luciferase transcription (data not shown).
To summarize, these studies demonstrate that the C termi-
nus of US28 is capable of constitutively trafficking other 7TM
receptors into the cytosol, but it does not transpose constitutive
signaling properties.
Substitution of the US28 C Terminus with Other 7TM C-
tails—Fig. 2 shows that US28300, the complete C-terminal
truncated version of US28, is still a highly constitutively active
receptor in all signaling assays employed (see Fig. 2, C–E).
However, the lack of the C terminus abolishes constitutive
endocytosis of this receptor (Fig. 2B, right panel). Substitution
of the US28 C terminus with (i) the rather long and serine/
threonine-rich C terminus of the NK1 receptor (Table I, F) or
(ii) the short C terminus of the viral ORF74 receptor (Table I,
G) onto the US28300 protein did not promote constitutive
endocytosis of US28 (Fig. 5, A and B). However, both US28-
NK1-ctail (f) and US28-ORF74-ctail () receptors signaled in a
constitutive manner like wild type US28 (‚). Both chimeric
receptors were highly constitutively active when measured in
gene dose-dependent inositol phosphate turnover (Fig. 5C),
CREB-luciferase (Fig. 5D), or NF-B transcription (Fig. 5E)
assays. In fact, the US28-NK1-ctail and US28-ORF74-ctail pro-
teins showed consistently higher constitutive activity than did
the wild type US28 receptor in all signaling assays employed.
Thus, the substitution of the US28 C terminus with C ter-
mini from two other 7TM receptors rather enhanced the con-
stitutive signaling activity of US28. In addition, both the long
and nonviral NK1 receptor c-tail as well as the short, viral
ORF74 receptor c-tail did not restore the constitutive endocytic
activity seen in the wild type receptor. Taken together, these
results suggest that the c-tail of US28 is both sufficient (even in
the absence of constitutive signaling activity) and necessary to
induce constitutive endocytosis of US28. These data also dem-
onstrate that the constitutive activity of US28 per se was not
sufficient to facilitate endocytosis of US28 receptors (i) lacking
the US28 c-tail or (ii) containing a different C terminus.
CX3CL1/Fractalkine Is an Agonist on US28 C-terminally
Deficient Receptors—US28 is known to bind a broad spectrum
of CC-chemokines (9, 10, 32, 33), but none of the CC-chemokine
ligands tested to date affect the constitutive signaling proper-
ties of US28 (6). However, US28 has been optimized to recog-
nize specifically the membrane-associated CX3C chemokine,
fractalkine/CX3CL1, with high affinity (10), and as we have
shown previously (5, 6), fractalkine/CX3CL1 is a partial inverse
agonist on US28 as assessed by inositol phosphate turnover
(Fig. 6A, ‚), CREB transcription activation (Fig. 6B, ‚), and
NF-B transcription (6). To our surprise, we found that fractal-
kine/CX3CL1 could increase constitutive inositol phosphate ac-
cumulation in both US28300 receptor (Fig. 6A, ) and US28-
NK1-ctail receptor (Fig. 6A, f) expressing COS-7 cells. The
same phenomenon was observed in HEK293 cells (and COS-7
cells, data not shown) co-transfected with the CREB-luciferase
reporter and either the US28300 receptor (Fig. 6B, ) or the
US28-NK1-ctail receptor (Fig. 6B, f) as well as in NF-B-
transcription assays (data not shown). The extent of fracta-
lkine/CX3CL1 stimulation above the base-line receptor activity
in both US28300 and US28-NK1-ctail-expressing cells was
almost reciprocal to that of its inverse agonist activity in cells
expressing the wild type US28 receptor.
Agonist Behavior of CX3CL1/Fractalkine Is Determined by
the Endocytic Properties of US28—The finding that CX3CL1/
fractalkine is a partial agonist on the C-terminally deficient
US28 proteins led us to speculate that fractalkine might in fact
be an agonist on US28, but its agonism is masked by the
constitutive endocytosis of the wild type receptor. If this were
the case, we would predict that blocking the endocytosis of
receptors and consequently increasing the number of receptors
on the cell surface at a given time would reveal the agonist
properties of CX3CL1/fractalkine. To examine this possibility,
we investigated the endocytic properties of the c-tail-deficient
proteins US28300 (Fig. 6C, ) and US28-NK1-ctail (Fig. 6C,
f) by measuring the internalization rates of these receptors
with 125I-CX3CL/fractalkine. Both US28300 and US28-NK1-
ctail showed markedly reduced internalization rates when
compared with wild type US28 (Fig. 6C,‚), thus resulting in an
increased receptor number on the cell surface at a given time as
assessed by whole cell saturation radioligand binding (for Bmax
and KD values see Table II).
DISCUSSION
The cytoplasmic tail of the majority of 7TM receptors typi-
cally determines their trafficking fate once they have been
activated by a given ligand and initiated a cellular signaling
cascade. Here we show that the cytoplasmic tail of the HCMV-
encoded chemokine receptor US28 regulates receptor endocy-
tosis in a ligand-independent, constitutively active manner and
that this feature is transposable to other 7TM receptors. We
FIG. 6. CX3CL1/fractalkine is an agonist on US28300 and US28-NK1-ctail proteins. A, effect of increasing concentrations of the
chemokine domain of fractalkine/CX3CL1 on the basal inositol phosphate turnover in COS-7 cells transiently transfected with 40 g of wild type
US28 (‚), US28300 receptor (), or US28-NK1-ctail (f) receptor DNAs. 100% corresponds to the maximally obtained basal activity with wild type
US28 receptor, and 0% corresponds to background activity obtained with 40 g of the empty expression vector pTEJ8. Results show the mean 
S.E. of 3 different experiments carried out in duplicate. B, HEK293 cells were transiently transfected with 50 ng of wild type US28 (‚), US28300
receptor (), or US28-NK1-ctail (f) receptor DNAs and 50 ng of CREB-luciferase cDNA. Cells were exposed to increasing concentrations of
fractalkine/CX3CL1 immediately following transfection. Shown are representative experiments out of at least four independent experiments
performed in quadruplicate. C, endocytosis of US28wt, US28300, and US28-NK1-c-tail proteins in the presence of CX3CL1/fractalkine. COS-7
cells were transiently transfected with either US28 wild type (‚), US28300 (), or US28-NK1-ctail constructs (f), and receptor internalization
was measured with 125I-CX3CL1 for 60 min at 37 °C. Data are mean  S.E. from 3 experiments performed in triplicate.
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show that constitutive activity and constitutive endocytosis are
separable entities in this viral chemokine receptor, and more
specifically, omittance of the US28 C terminus results in en-
hanced signaling capacity of the receptor. Moreover, we dem-
onstrate that the endocytic properties of a 7TM receptor can
camouflage the agonist properties of a ligand.
To test whether the constitutive endocytic activity of the
cytoplasmic tail of US28 was dependent on the constitutive
signaling activity of US28, we engineered the signaling-mute
US28 R129A receptor (Fig. 1). In both antibody feeding (Fig. 1,
A–N) and chemokine internalization assays (Fig. 1Q), US28
R129A was constitutively internalized similar to the wild type
receptor. To summarize, this was evidence that constitutive
endocytosis was totally independent of the signaling capacity of
the receptor and suggested that the US28-ctail per se is an
endocytic signal. In order to ask whether this constitutive
endocytic property of the US28 c-tail was transposable to other
7TM receptors, we chose two receptors that are predominantly
surface expressed as follows: the virally encoded, constitutively
active ORF74 receptor from herpes virus 8 (25) and the nonvi-
rally, nonconstitutively active human tachykinin NK1 receptor.
As Figs. 3 and 4 show, the endocytic functionality of the US28
c-tail was transposable to both the ORF74 and NK1 receptors.
The signaling properties of the NK1-US28-ctail chimera were
essentially undistinguishable from the wild type NK1 receptor
(Fig. 4F); however, the ORF74-US28-ctail receptor was totally
mute in all signaling assays employed (Fig. 3, C–E). We spec-
ulated that this was due to the fact that the far C-terminal
region of ORF74 is crucial for transducing signal information to
downstream effector proteins (26) and by substitution of this
“signaling domain” with the US28-ctail abolished the constitu-
tive signaling activity of ORF74.
A very recent study (20) showed that the C terminus of US28
is constitutively phosphorylated and that the deletion of all
phosphorylation sites resulted in increased surface expression
of US28. Both of our c-tail truncated mutants of US28 are
devoid of all but one (US28317 still contains serine 315)
characterized phosphorylation sites in this study. However, the
rather drastic protein modifications in US28317 and
US28300 did not impair the signaling capacities of these
receptors (Fig. 2, C and D). On the contrary, cells expressing
US28 constructs either (i) lacking the US28 C terminus, i.e.
US28300 and US28317, or (ii) carrying C-terminal substi-
tutions from other 7TM receptors, i.e. the US28-ORF74-ctail
and US28-NK1-ctail chimera, showed enhanced levels of con-
stitutive activity in inositol turnover, NF-B, and CREB tran-
scriptional activation when compared with the wild type recep-
tor (Figs. 2 and 5). This apparent “gain of function” might
simply reflect the fact that these receptors lack residues im-
portant for their sorting to late endosomes and multivesicular
bodies (7), and thus concentrate more on the cell surface and in
closer vicinity to their cognate G protein(s) (see Table II). This
in turn would result in more efficient signaling at a given time,
hence the increased level of activity.
Taken together, our experiments clearly demonstrate that
the C terminus of US28 contains sufficient information for the
constitutive internalization of 7TM receptors, independent of
the signaling capacity of the receptor.
To date, only one chemokine ligand modulating the consti-
tutive signaling activity of US28 has been identified, the mem-
brane-associated fractalkine/CX3CL1 (5, 6). Fractalkine/
CX3CL1 is a partial inverse agonist on wild type US28
receptors as assessed by inositol phosphate turnover, CREB
transcription activation (Fig. 6), and NF-B transcription (6)
and has been shown to induce some down-modulation of the
wild type US28 receptor (25% of receptor pool in 30 min) (7).
Strikingly, when testing fractalkine/CX3CL1 on the US28-c-
tail-deficient receptors, we observed a dose-dependent increase
in signaling activity in both the US28300 and the US28-NK1-
ctail receptors (Fig. 6). Neither US28300 nor US28-NK1-ctail
receptors are constitutively endocytosed, and in the presence of
CX3CL1, the endocytosis rates of these two receptors was sig-
nificantly reduced compared with the wild type US28 receptor
(Fig. 6C). We hence speculated that fractalkine might in fact be
an agonist on US28; however, because the wild type US28
receptor is rapidly internalizing, the agonist signaling proper-
ties of fractalkine are simply undetectable. US28 receptors
devoid of their constitutively internalizing C termini reveal the
true agonistic strength of fractalkine, because US28 is now
concentrated predominantly on the surface of the cell. It is
tempting to speculate that the concentration of US28 receptor
on the surface of the cell reflects a more in vivo like setting.
Evidence for this is found in the striking study of Streblow et al.
(12), in which US28 was able to mediate the migration of
smooth muscle cells in response to the chemokines RANTES/
CCL5 and MCP-1/CCL2, thus suggesting US28 to be one of the
possible causative agents in the pathogenesis of atherosclerosis
and restenosis. In this study, immunofluorescence analysis of
smooth muscle cells infected with an adenovirus carrying a
FLAG-tagged US28 receptor indicated that US28 was present
on the plasma membrane of these cells in a polarized fashion,
suggesting that US28 was concentrated at the leading edge of
smooth muscle cells when exposed to a chemokine gradient.
Hence, it might be feasible that in certain cellular environ-
ments combined with certain extracellular stimuli, US28 is
indeed expressed to a greater extent on the plasma membrane
than generally observed in the laboratory used heterologous
expression systems.
From a virological point of view, US28 is likely to be located
intracellularly in cell types that provide the best environment
for the replication and spreading of the virus, thereby acting as
an immediate early gene to up-regulate cellular transcription
factors like CREB or NF-B as suggested previously (6, 34, 35).
However, other cell types might provide different sorting
and/or interaction protein partners for US28, resulting in a
more pronounced surface expression of the receptor, which
then in turn becomes more susceptive to extracellular stimuli,
such as fractalkine. In these cell types, fractalkine might in fact
now act as an agonist, eventually leading to aberrant cell
growth and pathological phenotypes (12), an unpleasant side
effect of HCMV infections.
From a drug developmental point of view, the striking find-
ing that constitutive receptor endocytosis can mask the true
agonistic properties of a ligand might have important implica-
tions in the generation of more effective therapeutic agents. A
variety of constitutively activating mutations for 7TM recep-
tors has been implicated to be causative agents in the develop-
ment of diseases. For example, mutations in the thyrotropin
and luteotropin receptors cause thyrotoxicosis (36) and prema-
ture puberty (37), respectively. One might envision that the
treatment of such constitutively signaling receptors with an
“apparent” inverse agonist, which in pathophysiological cellu-
lar environments is truly a “camouflaged agonist,” might in fact
lead to the opposite rather than the desired therapeutic effect.
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